Answers are grounded in this paper and cite their sources.
Purpose Chemotherapy remains the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC), while the benefit of adding immunotherapy remains controversial. In this study, we evaluated the efficacy and safety of first-line immuno-chemotherapy in advanced PDAC. Methods This retrospective study included 203 patients with advanced PDAC treated at the First Affiliated Hospital, Sun Yat-sen University. Patients received chemotherapy alone (CT, n = 114) or chemotherapy plus PD-1/PD-L1 inhibitors (ICT, n = 89). Survival outcomes, safety, and exploratory genomic biomarkers were analyzed. Results The ICT group showed significantly longer median overall survival compared with the CT group (19.2 vs. 14.3 months, Hazard Ratio [HR] = 0.62, p = 0.011). The restricted mean survival time (RMST) for progression-free survival at 12 months was significantly longer in the ICT group compared with the CT group (RMST 0−12 = 8.61 vs. 7.13 months; 95% CI 0.36–2.60, p = 0.010). Disease control rate was significantly higher in the ICT group (86.5% vs. 63.2%, p < 0.001), while overall response rate had no significant difference (16.8% vs. 15.8%, p = 0.839). No significant differences were observed in the incidence or severity of treatment-related adverse events between the two groups. Genomic analysis (n = 67) showed that patients with TP53 mutations derived a significant survival benefit from ICT (HR = 0.19, p = 0.018). Conclusion Compared to chemotherapy alone, first-line ICT is associated with a significant improvement in overall survival in advanced PDAC, and may offer an early survival advantage.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: